U.S. President-elect Joe Biden will formally introduce his top economic policy advisers on Tuesday as his administration prepares to take power amid a slowing economic recovery hampered by the resurgent coronavirus pandemic. Biden will appear at an event in his hometown of Wilmington, Delaware, alongside his selections for senior roles, including his nominee for U.S. Treasury secretary, former Federal Reserve Chair Janet Yellen.
Canberra, Dec 1 (PTI) Left chasing shadows in the first two games, a listless Indian team would most certainly tweak its bowling combination in order to avoid a second successive clean-sweep when it takes on Australia in the third and final ODI here on Wednesday.
Spot an early Christmas gift for yourself? This article, Starbucks Malaysia launches designer merch with Kate Spade New York, originally appeared on Coconuts, Asia's leading alternative media company.
The Client Solid-State Drive Market will grow by USD 746.29 mn during 2020-2024
Georgia voters on Tuesday are choosing the short-term replacement for civil rights legend John Lewis. Former Atlanta City Council member Kwanza Hall and former Morehouse College President Robert Franklin are contesting a runoff election. The men finished first and second, but no one won a majority in a first round of voting in September among seven candidates.
Los Angeles, Dec 1 (PTI) Game of Thrones alum Peter Dinklage has found his next project in Legendary's new Toxic Avenger film.
These actors and actresses have redefined the ways to remain fit, healthy and strong, all of which can be done from the comforts of your home.
Gajjan Singh is the 3rd farmer to die during the protests over the 3 farmer laws passed by the Centre in September.
Karachi, Dec 1 (PTI) Comparison with modern-day greats like Virat Kohli makes Babar Azam proud but young Pakistan skipper aspires to be on a pedestal from where comparison are drawn with him.
Washington [US], December 1 (ANI): Scientists at Harvard University, the Broad Institute of MIT and Harvard, and MIT have developed a technology to investigate the function of many different genes in many different cell types at once, in a living organism.
Some 12% of Brits said they plan to spend 'significantly less' than last year, according to a new survey.
‘Moving mountains’: How Pakistan’s ‘invisible’ women won workers’ rightsHome workers in Sindh province are celebrating new social security benefits, after being denied lockdown funding
The 50 best albums of 2020: 50-41Today we begin our countdown of the best albums of the year, with poetic pop, avant-jazz and confessional disco
Britons were the lockdown bingers of Europe, finds studySnacking and drinking rose most in the UK out of 10 European countries since Covid
Matt Hancock under pressure to explain £30m test tube work for ex-neighbourAlex Bourne’s firm only recently gained safety certification for Covid testing product and had no experience in medical supplies * Coronavirus – latest updates * See all our coronavirus coverage
Philip Green's wealth has shrunk as Arcadia's fortunes have faded. Tycoon and wife had estimated fortune of £4.9bn in 2006 but it has fallen to about £950m
The Zirconium market will register an incremental spend of about $ 75 billion, growing at a CAGR of 3.11% during the five-year forecast period.
Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook
WISeKey International Holding Ltd Announces Extraordinary General Meeting of Shareholders Zug, Switzerland, December 1, 2020 – WISeKey International Holding Ltd (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, announced today that the Board of Directors has recommended certain proposals for shareholder approval at an Extraordinary General Meeting of Shareholders (“EGM“). The EGM is expected to be held at 2pm CET on January 28, 2021. Due to the extraordinary situation in connection with the COVID-19 pandemic, WISeKey's Board of Directors has decided to make use of the authority granted to it under the Swiss Federal Council Ordinance No. 3 on Measures to Combat the Coronavirus dated June 19, 2020 and require shareholders to exercise their voting rights at the EGM solely by giving electronic or written voting instructions to WISeKey's independent voting rights representative, as further described in the invitation to the EGM, which will be published on or about December 11, 2020. It will not be possible for shareholders to attend the EGM in person. The Board of Directors recommends shareholders to approve, among other things: * The creation of a special authorized share capital for the issuance of up to 12,327,506 new registered shares, par value CHF 0.05 each ("Class B Shares"), to arago GmbH’s ("arago") sole shareholder apart from WISeKey, Mr. Hans-Christian Boos, or companies controlled by him, in exchange for all arago shares directly or indirectly held by Mr. Hans-Christian Boos.As previously disclosed, WISeKey reached a binding agreement with arago for WISeKey to acquire through conversion of loan commitments and by guaranteeing arago's existing indebtedness, a majority interest of 51% in arago. The acquisition of a controlling interest in arago is only the initial step in an overall transaction that would lead to a combination of the businesses of WISeKey and arago. If and when definitively agreed, the combination would be completed through the issuance by WISeKey of Class B Shares to arago’s remaining minority shareholder against contribution to WISeKey of all arago shares not yet held by WISeKey. The Board of Directors would only make use of its authority if binding agreements are executed and all conditions precedent to closing are satisfied. * The election of Mr. Hans-Christian Boos, Managing Director and Founder of arago, as a new members of the Company's Board of Directors, for a term extending until the next annual general meeting of shareholders. Mr. Boos studied computer science at ETH Zurich and the Technical University of Darmstadt. His ongoing research focuses on graph theory, machine reasoning and machine learning. Mr. Boos is a member of the Digital Council advising the German Chancellor on digital policy and artificial intelligence. * An increase of the Board of Directors' general authority to issue shares out of authorized share capital, corresponding to approximately 25.65% of the Company's share capital (including the shares issued out of conditional share capital over 2020), in addition to the above-mentioned special authorized share capital for arago’s sole shareholder, for a further two-year period. The Board of Directors does not currently have specific plans to issue shares under the proposed general authorization. The Board of Directors believes, however, that providing the flexibility to issue shares quickly is a strategic benefit for the Company. * The creation of a conditional share capital on the basis of which the Company would have authority to issue registered shares, par value CHF 0.01, i.e. the Company's shares not listed on the SIX Swiss Exchange ("Class A Shares"), to members of the Board of Directors and executive management. This proposed conditional share capital provides authority to issue Class A Shares representing approximately 4.75% of the Company's share capital. The Board of Directors intends to implement a new "Class A Share WISeKey Stock Option Plan" pursuant to which members of the Board of Directors and the Company's executive management could, subject to the plan being resolved upon and approved by the Board of Directors, receive options or other awards exercisable for Class A Shares. The Board of Directors believes that issuing Class A Shares, which are non-tradeable, will be beneficial to the Company, as it will require directors and executive management members to focus on the long-term strategy and development of the Company. * An increase of the Company’s conditional share capital whereby Class B Shares representing approximately 32.82% of the Company's share capital (including the shares issued out of conditional share capital over 2020) will be reserved for Class B issuances in connection with convertible or similar financial instruments, and approximately 12.44% for Class B issuances under the WISeKey Stock Option Plan for the benefit of directors, executives, employees and consultants.A short presentation of the agenda items by Carlos Moreira, CEO of WISeKey, and Peter Ward, CFO, will be available soon in the ‘Investors Relations’ section of the WISeKey website. In addition, Dourgam Kummer has informed the Company that he will step down as a member of the Board of Directors with immediate effect. The Board thanks Mr. Kummer for his outstanding contribution to the Company.About WISeKey WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.). WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com.Press and investor contacts:WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 firstname.lastname@example.orgWISeKey Investor Relations (US) Contact: Lena Cati The Equity Group Inc. Tel: +1 212 836-9611 email@example.com Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any shares or other securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FInSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors, will give a presentation at the ISGE (International Society of Gynecological Endocrinology) 19th World Congress Virtual Edition, December 2-5, 2020. Dr Loumaye’s presentation will take place during the symposium available on demand on Friday December 4th from 08:00 am GMT and accessible for 4 months. The link to the Congress and sessions will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.comSymposium: IVF AND PREGNANCY: Recent development in IVFDate: Friday December 4thTitle: The use of a novel oxytocin receptor antagonist, nolasiban, prior to embryo transfer: does it help? About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com. About Nolasiban Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights (ex China). Cautionary Note Regarding Forward Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, , ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact: CEO Office contact Shauna Dillon Shauna.firstname.lastname@example.org +41 22 552 1550 Attachment * Press Release in Pdf